<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006682</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068284</org_study_id>
    <secondary_id>WHC-2000056</secondary_id>
    <secondary_id>NCI-V00-1631</secondary_id>
    <nct_id>NCT00006682</nct_id>
  </id_info>
  <brief_title>Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>An Open-Label Phase II Study of Navelbine (Vinorelbine Tartrate) and Taxotere (Docetaxel) as First-Line Therapy for Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of vinorelbine combined with docetaxel in&#xD;
      treating women who have metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the response rate in women with metastatic breast cancer treated&#xD;
      with vinorelbine and docetaxel. II. Determine the time to disease progression, time to&#xD;
      treatment failure, response duration, and survival in this patient population treated with&#xD;
      this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients receive vinorelbine IV on days 1 and 8, and&#xD;
      docetaxel IV over 1 hour on day 1 only. Treatment continues every 21 days in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients are followed for 1 month, and then&#xD;
      every 1.5-3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 69 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">January 22, 2002</completion_date>
  <primary_completion_date type="Actual">January 22, 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-Label Navelbine (vinorelbine tartrate) and Taxotere (docetaxel) as First-Line Therapy for Metastatic Breast Cancer</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Docetaxel 70mg/m2 on day 1 of every 21-day cycle</description>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine ditartrate</intervention_name>
    <description>Navelbine 20mg/m2 on Day 1 and D8 of a 21-day cycle</description>
    <other_name>Navelbine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage IV breast cancer&#xD;
        Disease progression following prior adjuvant chemotherapy (no disease progression during&#xD;
        treatment with prior doxorubicin) Bidimensionally measurable disease Prior radiotherapy&#xD;
        allowed if disease completely outside radiation port or histologic evidence of measured&#xD;
        area indicating malignancy and not radiation fibrosis No CNS metastases Brain metastases&#xD;
        previously treated with radiotherapy or surgical excision allowed if no evidence of&#xD;
        residual metastases on brain CT or MRI Hormone receptor status: Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Over 18 Sex: Female Menopausal status: Premenopausal or&#xD;
        postmenopausal Performance status: ECOG 0-1 Life expectancy: Greater than 16 weeks&#xD;
        Hematopoietic: WBC at least 2,000/mm3 Platelet count greater than 100,000/mm3 Hemoglobin&#xD;
        greater than 9 g/dL Hepatic: Bilirubin less than 2.0 mg/dL SGOT/SGPT less than 1.5 times&#xD;
        upper limit of normal (ULN) Alkaline phosphatase less than 2.5 times ULN Renal: Not&#xD;
        specified Cardiovascular: No symptomatic New York Heart Association class II or greater&#xD;
        congestive heart failure No significant arrhythmia requiring drug therapy No myocardial&#xD;
        infarction within the past 6 months No uncontrolled cardiac disease or unstable angina&#xD;
        Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective&#xD;
        contraception No other malignancy within the past 5 years except basal cell skin cancer or&#xD;
        carcinoma in situ of the cervix No preexisting clinically significant peripheral neuropathy&#xD;
        (no prior neuropathy of any grade if previously treated with paclitaxel) No unstable,&#xD;
        preexisting medical condition No serious active infection No other underlying medical,&#xD;
        psychological, familial, sociologic, or geographic condition that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 7 days since prior hematopoietic&#xD;
        growth factors (filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa) At least 7 days&#xD;
        since prior platelet transfusion Chemotherapy: See Disease Characteristics No prior vinca&#xD;
        alkaloids (including vinorelbine or docetaxel) No other concurrent antineoplastic agents&#xD;
        Endocrine therapy: No concurrent anticancer hormonal agents Radiotherapy: See Disease&#xD;
        Characteristics No concurrent palliative radiotherapy Surgery: See Disease Characteristics&#xD;
        Other: No other concurrent investigational drug or device&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Perry, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medstar Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Cancer Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2001</verification_date>
  <study_first_submitted>December 6, 2000</study_first_submitted>
  <study_first_submitted_qc>May 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2004</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

